Two most comprehensive randomized, double-blinded, placebo-controlled phase III clinical trials using MAGE-A3 as target antigen in cancer vaccines, named MAGRIT and DERMA, were carried out for NSCLC and melanoma treatment, respectively [161,162]. Here, MAGEA3 is linked to cancer.